SELECT was a large study focused on obesity and cardiovascular disease in people without type 2 diabetes, but it included kidney outcomes as a secondary end point. The data showed that semaglutide ...

Add Yahoo as a preferred source to see more of our stories on Google. GLP-1 weight-loss drugs like Ozempic or SGLT2 diabetes medications like Jardiance or Farxiga both helped protect the health of ...

Two classes of diabetes drugs may also improve cardiovascular and kidney disease outcomes in people with or without diabetes. In a meta-analysis involving more than 70,000 patients with diabetes, ...

New VA database study is the latest to find a small but significant increased risk for nonarteritic anterior ischemic optic neuropathy.

Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit: Kathryn Gamble for The Washington Post via Getty Images. According to the International Diabetes ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors — a class of drugs used to treat type 2 diabetes — could also prevent dementia, according to a study published Wednesday in The BMJ. The authors ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk for dementia and Parkinson’s disease, a new study finds. The report was ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

A BMJ guideline put patient risk into the equation for assessing the suitability of SGLT-2 inhibitors and GLP-1 receptor agonist drugs for type 2 diabetes. Their use in type 2 diabetes was only ...